(56) **References Cited**

U.S. PATENT DOCUMENTS

5,223,248	A	6/1993	McNamara et al.
5,238,686	A	8/1993	Eichel et al.
5,258,371	A	11/1993	Golub et al.
5,260,292	A	11/1993	Robinson et al.
5,277,916	A	1/1994	Dwyer et al.
5,283,065	A	2/1994	Doyon et al.
5,286,497	A	2/1994	Hendrickson et al.
5,300,304	A	4/1994	Sheth et al.
5,308,839	A	5/1994	Golub et al.
5,321,017	A	6/1994	Golub et al.
RE34,656	E	7/1994	Golub et al.
5,348,748	A	9/1994	Sheth et al.
5,413,777	A	5/1995	Sheth et al.
5,449,688	A	9/1995	Wahl et al.
5,459,135	A	10/1995	Golub et al.
5,505,949	A	4/1996	Benitez
5,517,049	A	5/1996	Huang
5,523,297	A	6/1996	Pruzanski et al.
5,532,227	A	7/1996	Golub et al.
5,674,539	A	10/1997	Tomas
5,753,711	A	5/1998	Schwabe et al.
5,770,588	A	6/1998	McNamara et al.
5,773,430	A	6/1998	Simon et al.
5,789,395	A	8/1998	Amin et al.
5,792,446	A	8/1998	Ashley
5,827,503	A	10/1998	Schwabe
5,827,840	A	10/1998	Ramamurthy et al.
5,834,449	A	11/1998	Thompson et al.
5,837,696	A	11/1998	Golub et al.
5,908,838	A	6/1999	Gans
5,919,775	A	7/1999	Amin et al.
5,929,055	A	7/1999	Ryan et al.
5,977,091	A	11/1999	Nieman et al.
5,998,390	A	12/1999	Ramamurthy et al.
6,015,803	A	1/2000	Wirostko
6,015,804	A	1/2000	Golub et al.
6,043,231	A	3/2000	Pruzanski et al.
6,100,248	A	8/2000	Golub et al.
6,114,316	A	9/2000	Ramamurthy et al.
6,133,310	A	10/2000	Parks
6,143,506	A	11/2000	Golub et al.
6,217,904	B1	4/2001	Midha et al.
6,228,398	B1	5/2001	Devane et al.
6,322,819	B1	11/2001	Burnside et al.
6,344,215	B1	2/2002	Bettman et al.
6,372,255	B1	4/2002	Saslawski et al.
6,455,583	B1	9/2002	Pflugfelder et al.
6,485,746	B1	11/2002	Campbell et al.
6,500,457	B1	12/2002	Midha et al.
6,506,740	B1	1/2003	Ashley et al.
6,610,274	B1	8/2003	Gardner
6,638,922	B2	10/2003	Ashley et al.
6,663,888	B2	12/2003	Percel et al.
6,664,287	B2	12/2003	Avery et al.
6,673,843	B2	1/2004	Arbiser
6,730,320	B2	5/2004	Rudnic et al.
6,913,768	B2	7/2005	Couch et al.
6,953,593	B2	10/2005	Kuhrts
7,008,631	B2	3/2006	Ashley
7,014,858	B2	3/2006	Ashley
7,211,267	B2	5/2007	Ashley
7,232,572	B2	6/2007	Ashley
8,052,983	B2	11/2011	Ashley
8,394,405	B2	3/2013	Chang et al.
8,394,406	B2	3/2013	Chang et al.
8,470,364	B2	6/2013	Chang et al.
2002/0004499	A1	1/2002	Rudnic et al.
2002/0136766	A1	9/2002	Rudnic et al.
2003/0082120	A1	5/2003	Milstein
2003/0096008	A1	5/2003	Rudnic et al.
2003/0130240	A1	7/2003	Ashley
2003/0139380	A1	7/2003	Ashley
2004/0014731	A1	1/2004	Golub et al.
2004/0063674	A1	4/2004	Levy et al.
2004/0115261	A1	6/2004	Ashley
2004/0142035	A1	7/2004	Chang et al.
2004/0147492	A1	7/2004	Ashley
2006/0094697	A1	5/2006	Ashley

FOREIGN PATENT DOCUMENTS

JP	02-006437	A	1/1990
WO	WO 83/00628	A1	3/1983
WO	WO 96/16648	A1	6/1996
WO	WO 98/05340	A1	2/1998
WO	WO 99/58131	A1	11/1999
WO	WO 00/18353	A2	4/2000
WO	WO 00/23055	A1	4/2000
WO	WO 01/87823	A1	11/2001
WO	WO 02/080932	A1	10/2002
WO	WO 02/083106	A1	10/2002

OTHER PUBLICATIONS

"CollaGenex Pharmaceuticals Reports Statistically and Clinically Significant Results from Dermostat Acne Study," Business Wire, Oct. 1, 2001, 3 pages.

"Humans Have Ten Times More Bacteria Than Human Cells: How Do Microbial Communities Affect Human Health," ScienceDaily (Jun. 5, 2008), http://www.sciencedaily.com/releases/2008/06/080603085914.htm, 3 pages.

Adams et al., "Topical Fusidic Acid Versus Peroral Doxycycline in the Treatment of Patients with Acne Vulgaris of the Face," *Cur. Therapeutic Res.* (1991) 50(2):268-273.

Akamatsu et al., "Effect of Doxycycline on the Generation of Reactive Oxygen Species: A Possible Mechanism of Action of Acne Therapy with Doxycycline," *Acta. Dorm. Venereal.* (Stockh) (1992) 72:178-179.

Akamatsu et al., "Effect of Keigai-Rengyo-To, A Japanese Kampo Medicine, on Neutorphil Functions: A Possible Mechanism of Action of Keigai-Rengyo-To in Acne," *J. Int'l Med. Res.* (1997) 25:255-265.

Akamatsu et al., "Effect of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism," Arch. Dermatol. Res. (1991) 283:524-528.

Akamatsu et al., "Effects of Subminimal Inhibitory Concentrations of Erythromycin, Tetracycline, Clindamycin, and Minocycline on the Neutrophil Chemotactic Factor Production in *Propionibacterium acnes* Biotypes 1-5", The Journal of Dermatology, (1991), 18, 247-251.

Akpek et al., "Ocular Rosacea," *Ophthalmology* (Nov. 1997) 104(11):1863-1867.

Amin et al., "A Novel Mechanism of Action of Tetracyclines: Effects on Nitric Oxide Synthases," *Proc. Nat'l Acad. Sci.* (Nov. 1996) 93:14014-14019.

Amin et al., "The Expression and Regulation of Nitric Oxide Synthase in Human Osteoarthritis-affected chondrocytes: Evidence for Up-regulated Neuronal Nitric Oxide Synthase," *J. Exp. Med.* (Dec. 1995) 182:2097-2102.

Baer et al., "High-Dose Tetracycline Therapy in Severe Acne," *Arch. Dermatol.* (Apr. 1976) 112:479-481.

Bartholomew et al., "Oxytetracycline in the Treatment of Ocular Rosacea: A Double-Blind Trial," *Brit J. Opth.* (1982) 66:386-388.

Batista et al., "Nitric oxide synthesis and severity of human periodontal disease", *Oral Diseases* (2002) 8, 254-260.

Bayomi et al., "Preparations and Dissolution Characteristics of Prolonged Release Mebeverine-HCL Beads," Drug Development and Industrial Pharmacy, 1994, 20(17):2763-2773.

Berger, Richard S., M.D., "A Double-Blind, Multiple-Dose, Placebo-Controlled, Cross-Over Study to Compare the Incidence of Gastrointestinal Complaints in Healthy Subjects Given Doryx R and Vibramycin R," J. Clin. Pharmacol., 1988, 28:367-370.

Bikowski et al., "Treatment of rosacea with doxycycline monohydrate," *Cutis* (Aug. 2000) 66:149-152.

Bikowski, J., Examining Inflammation as a Common Factor in Theories of Rosacea Pathophysiology, www.rosacea.com, 2006, (available at http://web.archive.org/web/20080607070740/http://www.rosaceatoday.com/TheoriesofRosacea.asp).